Article Text

AB0724 Higher likelihood of anti-tnf prescription in men vs women with ankylosing spondylitis despite similar disease burden: results from routine care at two academic rheumatology centers of usa and spain
  1. M Blasco-Blasco1,
  2. I Castrejόn2,
  3. M Ruiz-Cantero1,
  4. V Jovaní3,
  5. E Pascual4,
  6. J Block2,
  7. T Pincus2
  1. 1Public Health, University of Alicante, Alicante, Spain
  2. 2Rheumatology, Rush University Medical Center, Chicago, United States
  3. 3Rheumatology, Alicante University General Hospital
  4. 4Rheumatology, Miguel Hernandez University, Alicante, Spain


Background Ankylosing spondylitis (AS) has been considered to be more prevalent in men compared to women. Besides, the clinical presentation in women is thought to be milder and more peripheral than in men. Some studies have suggested a higher burden of disease in women1,2 but others not confirm these differences3,4.

Objectives To evaluate possible gender differences in men and women with AS seen in routine care at two academic rheumatology centers of the USA and Spain.

Methods Sixty one men and 30 women with AS in Spain and 61 men and 31 women in the USA completed a Multidimensional Health Assessment Questionnaire (MDHAQ). The MDHAQ includes (0–10 scores) for physical function, pain, patient global estimate (PATGL), compiled into a 0–30 RAPID3, and fatigue scores. Furthermore, demographic data, biological (anti-TNFα) and DMARD therapies, were obtained from the medical records. A comparative analysis of men and women was performed by Mann-Whitney U tests for non-parametric quantitative data (median/interquartile range), and Chi square tests for qualitative data (frequencies/percentajes).

Results We have not detected significant differences in men and women for function, pain, PATGL, or fatigue although a trend towards higher RAPID3 values was seen in females in both sites (Table). Anti-TNFα medications were prescribed more often in men than in women (81.2% vs 65.6%, in all patients p=0.02), statistically significant in Spain (82% vs 60%, p=0.02), and numerically higher in the USA (80.3% vs 71%, p=0.31). DMARD medications tend to be more prescribed in women than men in all patients (17.2% vs 23%, p=0.35) although no statistically significant.

Table 1.

Health status and treatment of patients with SpA at two academic centers (*p<0.05)

Conclusions Men with SpA receive anti-TNFα more likely than women; although disease burden appears somewhat higher in women. This pattern is similar in both Spain and the USA, though statistically significant only in the Spanish population. Other parameters may be having weight in the management of SpA, such as radiographic signs versus peripheral manifestations.


  1. van der Horst-Bruinsma IE, et al. Ann Rheum Dis 2013.

  2. Ortega Castro R, et al. Reumatol Clin 2013.

  3. Gremese E, et al. Rheumatology (Oxford) 2014.

  4. Shahlaee A, et al. Clin Rheumatol 2015.


Acknowledgements University Institute for Gender Studies (University of Alicante) supported MBB.

Disclosure of Interest M. Blasco-Blasco: None declared, I. Castrejόn: None declared, M. Ruiz-Cantero: None declared, V. Jovaní: None declared, E. Pascual: None declared, J. Block: None declared, T. Pincus Shareholder of: Health Report Services, Inc.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.